Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2895852 | 0.99 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTHSD17B10RAB9A | |
| SCHEMBL5950091 | 0.85 | GAA (0.46) | SMN1; SMN2ALDH1A1MAPTHSD17B10RAB9A | |
| SCHEMBL3504414 | 0.83 | TSHR (0.56) | SMN1; SMN2ALDH1A1MAPTHSD17B10RAB9A | |
| SCHEMBL3976847 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1MAPTHSD17B10RAB9A | |
| Hydrochloric Acid SCHEMBL7201470 | 0.77 | MCL1 (0.53) | ALDH1A1MAPTHSD17B10HPGDGAA | |
| SCHEMBL693 | 0.77 | TSHR (0.47) | ALDH1A1MAPTHSD17B10RAB9AKDM4E | |
| SCHEMBL4123607 | 0.77 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1MAPTHSD17B10RAB9A | |
| SCHEMBL2899318 | 0.77 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1MAPTHSD17B10RAB9A | |
| SCHEMBL3731320 | 0.75 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1MAPTHPGDKDM4E | |
| SCHEMBL27597683 | 0.74 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MAPTHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366016-B1 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| US-7709677-B2 | e.g.3-{3-[(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]phenyl}isonicotinic acid ; useful as agonists at atypical beta-adrenoceptors; treatment of hyperglycaemia, animal growth promoters, blood platelet aggregation inhibitors, as positive inotropic agents and antiatherosclerotic agent | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709677-B2 | e.g.3-{3-[(2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}ethyl)amino]phenyl}isonicotinic acid ; useful as agonists at atypical beta-adrenoceptors; treatment of hyperglycaemia, animal growth promoters, blood platelet aggregation inhibitors, as positive inotropic agents and antiatherosclerotic agent | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080306278-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306278-A1 | PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-7425639-B2 | For preparing arylethanoldiamines which are agonists of beta-adrenoceptors; fewer steps, the regioselectivity of epoxide opening is highly selective; novel chemical intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| CN-1487928-A | Compound (I) | — | 2004-04-07 | — | — | CN | disclosed |
| WO-2002066418-A2 | PROCESS FOR THE PREPARATION OF ARYLETHANOLDIAMINES USEFUL AS AGONISTS OF THE BETA-3-ADRENOCEPTOR | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306278-A1 | PROCESS | ADRB3, ADRA1D, ADRB1 | SMN1; SMN2 2635/4885ALDH1A1 459/4885MAPT 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.